• This marks the third milestone achieved under the collaboration and reflects the steady progress of the pipeline
• Under the terms of the agreement, Nxera is eligible to receive up to US$1.2 billion in potential option, development and commercial milestones, in addition to tiered royalties based on sales

Nxera Pharma Co., Ltd. (“Nxera” or “the Company”; TSE 4565) announces that it has reached a third R&D milestone under its multi-target discovery collaboration with AbbVie focused on neurological diseases, resulting in a payment of US$10 million to Nxera.

Nxera and AbbVie entered this multi-target collaboration in 2022 to leverage Nxera’s NxWave™ platform to discover novel medicines targeting G protein-coupled receptors (GPCRs) associated with neurological disease. This current milestone relates to the identification of validated and differentiated ‘hit’ molecules against a neurology target.

Under the terms of the agreement, Nxera is eligible to receive up to US$40 million in near-term research milestones, as well as further potential option, development and commercial milestones totalling up to US$1.2 billion, plus tiered royalties on global sales. This is the third milestone received in this collaboration; the first milestone was achieved in June 2024 and the second milestone in September 2025.

Christopher Cargill, President and CEO of Nxera Pharma, commented: “This third milestone marks an important step forward in translating our discovery capabilities into a growing pipeline of novel programmes within our collaboration with AbbVie. As this productive partnership continues, we are encouraged by the advancement of multiple targets and the potential to address significant unmet needs in neurological disease.”